Economic Assessment of Insulin Glargine and Insulin Determir for Type 2 Diabetes / 中国药房
China Pharmacy
;
(12)2001.
Artículo
en Chino
| WPRIM
| ID: wpr-533655
ABSTRACT
OBJECTIVE:
To conduct cost-effective analysis according to clinical trial results of foreign type 2 diabetic patients treated with insulin glargine and insulin determir in order to provide reference for application of basal insulin in China.METHODS:
Cost-minimization analysis was used due to the clinical trial results that two kinds of basal insulin had no significant differences in glycemic control. The cost of treatment was detected and evaluated from the perspective of medical insurance.RESULTS:
When insulin glargine and insulin determir had same effect on glycemic control and hypoglycemia risk, insulin glargine was 40.77% cheaper than insulin determir in terms of the yearly treatment cost. The cost of treatment of insulin glargine was cheaper than that of insulin glargine although some key factors were adjusted.CONCLUSION:
As compared with insulin determir, the cost of treatment is decreased by using insulin glargine for type 2 diabetic patients. Moreover, effect of insulin glargine on glycemic control is the same to insulin determir, which is advantage for controlling the increase of health expenditure.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Ensayo Clínico Controlado
/
Evaluación Económica en Salud
Idioma:
Chino
Revista:
China Pharmacy
Año:
2001
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS